VIP (Vasoactive Intestinal Peptide): Pulmonary, Immune & Neuroprotection Research

Written by NorthPeptide Research Team

For laboratory and research use only. Not for human consumption.

What Is Vasoactive Intestinal Peptide (VIP)?

Vasoactive intestinal peptide (VIP) is a 28-amino-acid neuropeptide belonging to the secretin/glucagon superfamily. It was first isolated from porcine duodenal tissue in 1970 by Sami Said and Viktor Mutt, who identified the peptide based on its potent vasodilatory activity. The name itself reflects this initial discovery context — the researchers observed that the compound produced profound vasodilation when administered intravenously, and it was isolated from intestinal tissue.

However, the name “vasoactive intestinal peptide” understates the molecule’s biological scope considerably. In the decades following its discovery, VIP has been identified in tissues far beyond the gastrointestinal tract. It is widely distributed throughout the central and peripheral nervous systems, the respiratory tract, immune cells, the cardiovascular system, and the reproductive organs. This broad tissue distribution reflects VIP’s role as a pleiotropic signaling molecule — one that participates in a diverse range of physiological processes including vasodilation, bronchodilation, immune regulation, neurotransmission, circadian rhythm entrainment, and gastrointestinal motility.

The amino acid sequence of VIP is:

His-Ser-Asp-Ala-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn-NH₂

VIP shares significant structural homology with other members of the secretin/glucagon superfamily, including pituitary adenylate cyclase-activating polypeptide (PACAP), secretin, and glucagon. This homology is reflected in overlapping receptor pharmacology — PACAP, for example, can activate VIP receptors, and vice versa, though with different affinities and potencies. Understanding these receptor cross-reactivities is important context for interpreting VIP research findings.

Mechanism of Action: VPAC1 and VPAC2 Receptors

VIP exerts its biological effects primarily through two G protein-coupled receptors: VPAC1 (also designated VIPR1) and VPAC2 (also designated VIPR2). Both receptors belong to the Class B (secretin-like) family of GPCRs, and both couple predominantly to the stimulatory G protein G_s, activating the adenylyl cyclase-cAMP-protein kinase A (PKA) signaling cascade.

VPAC1 Receptor

VPAC1 is widely expressed in the central nervous system, lungs, liver, intestinal epithelium, and T lymphocytes. Upon VIP binding, VPAC1 activation stimulates adenylyl cyclase, elevating intracellular cyclic AMP (cAMP) levels. This cAMP accumulation activates PKA, which phosphorylates downstream targets involved in cell survival, cytokine production, smooth muscle relaxation, and secretory processes.

In the immune system, VPAC1 has been a focus of considerable research interest. It is constitutively expressed on resting T cells, and VIP signaling through VPAC1 has been observed to shift the T helper cell balance from Th1 (pro-inflammatory) toward Th2 (anti-inflammatory) responses in preclinical models. This immunomodulatory property is a central feature of VIP’s research profile.

VPAC2 Receptor

VPAC2 is predominantly expressed in the suprachiasmatic nucleus (SCN) of the hypothalamus, smooth muscle, pancreatic acinar cells, and activated immune cells. VPAC2 also couples to G_s and activates the cAMP-PKA pathway, but its tissue distribution gives it a distinct functional profile compared to VPAC1.

In the SCN, VPAC2 has been identified as a critical component of the molecular clock machinery. VIP-VPAC2 signaling synchronizes the firing patterns of SCN neurons, and VPAC2 knockout studies in mice have demonstrated disrupted circadian rhythms, underscoring the importance of this receptor in circadian biology. VPAC2 is also upregulated on activated T cells and macrophages, suggesting a role in immune responses during active inflammation.

Downstream Signaling Beyond cAMP

While the G_s-adenylyl cyclase-cAMP pathway is the canonical signaling route for both VPAC receptors, research has identified additional downstream mechanisms:

• Phospholipase C (PLC) activation — In certain cell types, VIP receptor engagement has been observed to activate PLC, leading to inositol trisphosphate (IP3) production and intracellular calcium mobilization.
• NF-κB modulation — VIP has been shown to inhibit NF-κB transcription factor activity in macrophages and dendritic cells, reducing the expression of pro-inflammatory genes including TNF-α, IL-6, and IL-12.
• CREB activation — cAMP response element-binding protein (CREB) activation downstream of PKA has been implicated in VIP’s neuroprotective and anti-apoptotic effects observed in cell culture models.
• PI3K/Akt pathway — Some studies have reported VIP activation of the phosphoinositide 3-kinase (PI3K)/Akt survival pathway, potentially contributing to the cytoprotective effects observed in neuronal and epithelial cell models.

Research Applications

VIP’s broad receptor distribution and pleiotropic signaling have led to its investigation across a wide range of research domains. The following sections summarize the major areas of active investigation.

Pulmonary Research and Pulmonary Hypertension

VIP’s role in pulmonary physiology represents one of its most clinically advanced research areas. VIP is a potent bronchodilator and pulmonary vasodilator, and it is normally present in high concentrations in lung tissue, where it is released from nerve endings in airway and vascular smooth muscle.

Research by Said and colleagues demonstrated that VIP-deficient mice develop spontaneous features of pulmonary arterial hypertension, including elevated right ventricular pressures and pulmonary vascular remodeling. Conversely, VIP administration in animal models of pulmonary hypertension has been associated with reductions in pulmonary artery pressure, decreased right ventricular hypertrophy, and improved pulmonary vascular compliance.

These preclinical findings led to VIP receiving orphan drug designation from the FDA for the treatment of pulmonary arterial hypertension, a significant milestone that reflects the strength of the preclinical evidence. Small pilot studies in human subjects with pulmonary hypertension have reported improvements in hemodynamic parameters following inhaled VIP administration, though large-scale randomized controlled trials have not yet been completed.

CIRS and Mold Illness Research (Shoemaker Protocol)

One of the more distinctive areas of VIP research involves its use in the investigation of chronic inflammatory response syndrome (CIRS), particularly in the context of biotoxin exposure from water-damaged buildings. Dr. Ritchie Shoemaker and colleagues developed a multi-step treatment protocol for CIRS in which VIP occupies a specific role in the later stages of the intervention sequence.

In the Shoemaker protocol, VIP is investigated after other steps — including binder therapy, eradication of colonized organisms, and correction of markers such as MMP-9, VEGF, and C4a — have been completed. Research publications from the Shoemaker group have reported that VIP administration in this context was associated with normalization of inflammatory biomarkers, improvements in pulmonary function tests, and symptomatic improvements in patients meeting the CIRS case definition.

It is important to note that the CIRS/biotoxin illness paradigm and the Shoemaker protocol remain subjects of ongoing scientific debate. While published case series and observational data exist, large-scale randomized controlled trials evaluating VIP specifically for CIRS have not been completed. Researchers investigating this area should review both the supporting literature and the critical assessments of the CIRS framework.

Neuroprotection and Neurodegenerative Research

VIP is abundantly expressed in the central nervous system, where it functions as a neurotransmitter and neuromodulator. Its neuroprotective properties have been investigated in multiple preclinical models of neurological injury and disease.

In cell culture models, VIP has been observed to protect neurons against a range of insults, including glutamate excitotoxicity, beta-amyloid toxicity, oxidative stress, and inflammatory cytokine exposure. The mechanisms underlying these protective effects appear to involve cAMP-CREB signaling, upregulation of anti-apoptotic proteins (including Bcl-2), and suppression of microglial activation.

Animal model studies have extended these findings to in vivo contexts. In rodent models of Alzheimer’s disease, VIP administration has been associated with reduced amyloid plaque burden, decreased neuroinflammation, and improved performance on memory and learning tasks. In Parkinson’s disease models, VIP has been investigated for its potential to protect dopaminergic neurons in the substantia nigra. In traumatic brain injury models, VIP treatment has been associated with reduced lesion volume and improved neurological outcomes.

While these preclinical findings are consistent and span multiple research groups, translation to human neurodegenerative disease remains an open question. VIP’s short half-life in circulation (approximately 1-2 minutes due to rapid enzymatic degradation) presents a significant pharmacokinetic challenge for CNS delivery, and this has been an active area of drug delivery research.

Immune Modulation and Autoimmune Research

VIP is one of the most extensively studied endogenous immunomodulatory peptides. Its effects on immune function have been documented across multiple cell types and experimental systems. Researchers studying immune-modulating peptides may also find relevant context in guides covering Thymosin Alpha-1 and LL-37, which are investigated in overlapping immunological research contexts.

• Macrophage modulation — VIP has been observed to inhibit the production of pro-inflammatory cytokines (TNF-α, IL-6, IL-12) and nitric oxide by activated macrophages, while promoting the production of the anti-inflammatory cytokine IL-10.
• Dendritic cell tolerization — Research has demonstrated that VIP can induce a tolerogenic phenotype in dendritic cells, characterized by reduced expression of co-stimulatory molecules and increased IL-10 secretion. These tolerogenic dendritic cells have been investigated for their ability to generate regulatory T cells.
• T cell differentiation — VIP signaling through VPAC1 has been observed to promote Th2 differentiation and suppress Th1 and Th17 responses. VIP has also been investigated for its role in promoting regulatory T cell (Treg) generation and function.
• Anti-inflammatory peptide synergies — VIP’s immunomodulatory profile shares certain features with other peptides studied in inflammatory contexts. KPV, for example, has been investigated for its anti-inflammatory properties through distinct but potentially complementary mechanisms involving melanocortin receptor signaling.

In preclinical models of autoimmune diseases — including rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis (experimental autoimmune encephalomyelitis), and type 1 diabetes — VIP administration has been associated with reduced disease severity, decreased inflammatory infiltrate, and improved tissue preservation. These studies have established VIP as a reference compound in neuroimmune research.

Gastrointestinal Motility and Secretion

VIP’s original tissue of isolation — the gastrointestinal tract — remains an important area of research. VIP is released from enteric neurons throughout the GI tract, where it functions as a non-adrenergic, non-cholinergic (NANC) neurotransmitter.

In the GI system, VIP has been investigated for its roles in:

• Smooth muscle relaxation — VIP is the primary inhibitory neurotransmitter in many regions of the GI tract, mediating receptive relaxation of the stomach, relaxation of the lower esophageal sphincter, and descending inhibition during peristalsis.
• Water and electrolyte secretion — VIP stimulates intestinal secretion of water and electrolytes, a property that has been studied extensively in the context of secretory diarrhea. VIPomas — rare neuroendocrine tumors that produce excess VIP — cause profuse watery diarrhea (Verner-Morrison syndrome), providing clinical evidence of VIP’s secretory potency.
• Mucosal protection — Research has suggested that VIP may have cytoprotective effects on intestinal epithelium, potentially through modulation of inflammatory responses and maintenance of epithelial barrier integrity.

Circadian Rhythm Research

VIP plays a critical role in the master circadian pacemaker, the suprachiasmatic nucleus (SCN). Approximately 10-25% of SCN neurons produce VIP, and these VIP-expressing neurons are essential for synchronizing the circadian clock network.

Research using VIP knockout mice and VPAC2 knockout mice has demonstrated severe disruption of circadian behavioral rhythms, including loss of coordinated activity-rest cycles and impaired adaptation to light-dark transitions. At the cellular level, VIP signaling through VPAC2 has been shown to synchronize the molecular clock oscillations (Period, Cryptochrome, BMAL1, and CLOCK gene expression) across individual SCN neurons, enabling the nucleus to function as a coherent pacemaker.

This circadian research has implications for understanding sleep disorders, shift work adaptation, jet lag, and the broader connections between circadian disruption and metabolic, immune, and neurological function.

Dosing in Published Research Models

The following table summarizes dosing parameters reported in published preclinical and clinical research. These values reflect experimental protocols and are provided for research reference only. VIP has not been approved by the FDA for therapeutic use (apart from its orphan drug designation for pulmonary hypertension research).

Research Context	Route	Dose Range (Published Studies)	Frequency	Notes
Pulmonary hypertension (human pilot)	Inhaled (nebulized)	100–200 μg per inhalation	3–4 times daily	Pilot study data; inhaled route bypasses rapid systemic degradation
CIRS/Shoemaker protocol (observational)	Intranasal	50 μg per dose (each nostril)	4 times daily	Used in later stages of multi-step protocol after biomarker criteria are met
Autoimmune models (rodent)	Intraperitoneal	1–5 nmol per injection	Daily or every other day	Murine collagen-induced arthritis, EAE, colitis models
Neuroprotection (rodent)	Intracerebroventricular / IP	0.5–5 nmol	Single or repeated doses	Brain injury and neurodegeneration models
In vitro cell studies	Cell culture media	10-9 to 10-6 M	N/A	Macrophage, dendritic cell, neuronal, and epithelial culture systems

Important pharmacokinetic note: VIP has an extremely short circulating half-life of approximately 1-2 minutes due to rapid enzymatic degradation by dipeptidyl peptidase IV (DPP-IV), neutral endopeptidase, and other serum proteases. This rapid degradation is a significant consideration in research protocol design and has motivated investigation into alternative delivery routes (inhaled, intranasal), sustained-release formulations, and structurally modified VIP analogs with enhanced metabolic stability.

Reconstitution and Handling

Research-grade VIP is typically supplied as a lyophilized (freeze-dried) powder. Proper reconstitution and storage are essential for maintaining peptide integrity and experimental reproducibility.

Reconstitution Protocol

1. Allow the lyophilized vial to equilibrate to room temperature before opening.
2. Reconstitute with bacteriostatic water by adding the solvent slowly along the inside wall of the vial.
3. Swirl gently until fully dissolved. Do not shake or vortex vigorously — mechanical agitation can damage peptide structure and promote aggregation.
4. The reconstituted solution should be clear and colorless. Discard if turbidity or particulate matter is observed.
5. For concentrations that prove difficult to dissolve, brief gentle sonication or the addition of a small amount of dilute acetic acid (0.1%) may facilitate dissolution.

Storage Recommendations

Form	Storage Condition	Stability
Lyophilized (sealed)	-20°C (freezer)	12+ months
Lyophilized (sealed)	2–8°C (refrigerator)	6–12 months
Reconstituted solution	2–8°C (refrigerator)	Up to 30 days
Reconstituted aliquots	-20°C (frozen)	3–6 months

• Avoid repeated freeze-thaw cycles — aliquot reconstituted peptide into single-use volumes when planning multiple experimental timepoints.
• Protect from light — store vials in opaque containers or wrapped in foil.
• Minimize air exposure — use inert gas (nitrogen or argon) to displace headspace air in partially used vials when possible.

Purity and Quality Verification

Research-grade VIP should be characterized by HPLC purity (typically ≥95%, with ≥98% preferred for in vivo studies) and confirmed by mass spectrometry (expected molecular weight: ~3,326 Da). A certificate of analysis documenting purity, identity, peptide content, and endotoxin levels (for in vivo applications) is essential for experimental reproducibility. NorthPeptide VIP is supplied with third-party analytical documentation.

Safety Profile in Research

VIP’s safety profile in research models reflects both its endogenous nature and its potent biological activity. The following observations are drawn from published preclinical and limited clinical data.

Reported Observations in Human Studies

In the small number of human studies conducted with VIP (primarily pulmonary hypertension pilot studies and CIRS observational reports), the most frequently reported effects include:

• Transient hypotension — Consistent with VIP’s potent vasodilatory activity. This has been observed primarily with systemic (intravenous) administration and is generally less pronounced with inhaled or intranasal routes.
• Facial flushing — Related to vasodilation, typically transient.
• Diarrhea — Consistent with VIP’s known stimulatory effects on intestinal water and electrolyte secretion. This is dose-dependent and reflects VIP’s physiological role in GI secretory regulation.
• Nasal congestion — Reported with intranasal administration, likely related to local vasodilatory effects on nasal mucosa.

Preclinical Safety Observations

In animal models, VIP administration at research doses has generally been well tolerated. No evidence of mutagenicity, carcinogenicity, or organ toxicity has been reported in the preclinical literature at standard experimental doses. However, it should be noted that comprehensive formal toxicology studies meeting current Good Laboratory Practice (GLP) standards have not been published for VIP in the context of drug development applications.

Theoretical Considerations

• Immunosuppressive potential — VIP’s anti-inflammatory and Th2-skewing effects, while potentially beneficial in autoimmune research contexts, raise theoretical considerations about immune suppression with chronic administration. This has not been systematically evaluated in long-term studies.
• Tumor biology — VIP and its receptors have been detected in various tumor types, and VPAC receptors have been investigated as targets for tumor imaging. The relationship between VIP signaling and tumor biology is complex and context-dependent, warranting careful consideration in study design.
• Cardiovascular effects — VIP’s potent vasodilatory activity means that cardiovascular monitoring is warranted in any research protocol involving systemic administration, particularly in models with pre-existing hemodynamic compromise.

Limitations of Current Safety Data

The safety profile of VIP in humans is based on limited data from small pilot studies and observational case series. No large-scale, randomized, placebo-controlled safety trials have been completed. Long-term safety data in humans is essentially absent from the published literature. Researchers should design protocols with appropriate safety monitoring and consult relevant institutional review board guidance.

VIP in Context: Related Research Peptides

VIP’s research profile intersects with several other peptides studied in immunological, inflammatory, and neuroprotective contexts. Understanding these relationships may be useful for researchers designing comparative or combination studies.

Peptide	Primary Research Focus	Relationship to VIP Research
Thymosin Alpha-1	Immune modulation, T cell maturation	Studied alongside VIP in immune regulation research; different mechanism (thymic peptide vs. neuropeptide) but overlapping interest in T cell function and immune balance. See the Thymosin Alpha-1 research guide.
LL-37	Antimicrobial defense, innate immunity	Investigated in overlapping immune research contexts; LL-37 focuses on antimicrobial and innate immune mechanisms while VIP primarily modulates adaptive immune responses. See the LL-37 research guide.
KPV	Anti-inflammatory, melanocortin signaling	Both VIP and KPV are studied for anti-inflammatory properties in GI and systemic models; KPV acts through melanocortin receptors while VIP signals through VPAC1/2. See the KPV research guide.
PACAP (Pituitary Adenylate Cyclase-Activating Polypeptide)	Neuroprotection, stress response	Closest structural relative of VIP; shares VPAC1 and VPAC2 receptors but also activates PAC1 receptor. Important to distinguish VIP-specific vs. shared VPAC effects in research.

Summary

Vasoactive intestinal peptide is a 28-amino-acid neuropeptide with one of the broadest receptor distributions and most diverse functional profiles of any endogenous signaling molecule. Since its discovery by Said and Mutt in 1970, VIP has been the subject of extensive preclinical investigation spanning pulmonary physiology, neuroimmunology, gastrointestinal function, circadian biology, and autoimmune disease models.

Key points from the current research landscape:

• Well-characterized mechanism — VIP signals through VPAC1 and VPAC2 receptors via the G_s-adenylyl cyclase-cAMP-PKA pathway, with additional downstream effects on NF-κB, CREB, and PI3K/Akt signaling.
• Pulmonary research is the most clinically advanced area — Orphan drug designation for pulmonary arterial hypertension reflects the strength of preclinical evidence, though large-scale human trials remain pending.
• Immunomodulation is broadly documented — VIP’s effects on macrophages, dendritic cells, and T cell differentiation are among the most extensively characterized of any endogenous neuropeptide in the research literature.
• Neuroprotective properties are consistent across models — Multiple research groups have documented VIP’s protective effects against neuronal insults, though CNS delivery remains a pharmacokinetic challenge.
• Short half-life is a significant research consideration — VIP’s 1-2 minute circulating half-life has driven investigation into alternative delivery routes and stabilized analogs.
• Human clinical data remains limited — While pilot studies and observational reports exist, large-scale randomized controlled trials have not been completed for any indication.

VIP represents a well-studied endogenous peptide with a robust preclinical evidence base. As research progresses toward more rigorous human studies — particularly in pulmonary hypertension and neuroimmune applications — VIP’s position as a reference compound in neuropeptide and immunomodulatory research is likely to continue growing.

---

References

1. Said SI, Mutt V. “Polypeptide with broad biological activity: isolation from small intestine.” Science. 1970;169(3951):1217-8.
2. Delgado M, Pozo D, Ganea D. “The significance of vasoactive intestinal peptide in immunomodulation.” Pharmacol Rev. 2004;56(2):249-90.
3. Said SI. “Vasoactive intestinal peptide in pulmonary arterial hypertension.” Am J Respir Crit Care Med. 2012;185(7):786.
4. Aton SJ, Colwell CS, Harmar AJ, Waschek J, Herzog ED. “Vasoactive intestinal polypeptide mediates circadian rhythmicity and synchrony in mammalian clock neurons.” Nat Neurosci. 2005;8(4):476-83.
5. Brenneman DE. “Neuroprotection: a comparative view of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide.” Peptides. 2007;28(9):1720-6.
6. Gomariz RP, Juarranz Y, Abad C, Arranz A, Leceta J, Martinez C. “VIP-PACAP system in immunity: new insights for multitarget therapy.” Ann N Y Acad Sci. 2006;1070:51-74.
7. Shoemaker RC, House D, Ryan J. “Vasoactive intestinal polypeptide (VIP) corrects chronic inflammatory response syndrome (CIRS) acquired following exposure to water-damaged buildings.” Health. 2013;5(3):396-401.
8. Petkov V et al. “Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension.” J Clin Invest. 2003;111(9):1339-46.

---